Citations
1 publicationsPublications from researchers using this productDescription
Nedaplatin is a derivative of cisplatin and a DNA damage agent that can induce nephrotoxicity [1]. Nedaplatin enters cells through various transport proteins to bind to DNA, causing DNA distortion and damaging the DNA structure, and stimulates the production of reactive oxygen species, thereby inducing cellular oxidative stress[2]. Nedaplatin has been widely used to kill the proliferation of various tumor cells and has been employed to develop combined therapies to effectively inhibit tumor growth[3].
In vitro, Nedaplatin treatment for 48 hours significantly promoted cell death in HNE1 and CNE2 cells, with IC50 values of 2.75μg/ml and 1.49μg/ml, respectively[4]. Treatment with 10μg/ml Nedaplatin for 48 hours significantly induced apoptosis in SKOV3 cells, caused cell cycle arrest, accompanied by an increase in the expression of Bax, caspase-3 and caspase-9, and a decrease in the expression of Bcl-2 and MMP-2[5]. Treatment with 20μM Nedaplatin combined with 5μM ABT-737 for 48 hours led to depolarization of the mitochondrial membrane in A549 cells, promoting the degradation of Mcl-1 protein and the release of cytochrome c[6].
In vivo, Nedaplatin treatment via a single intravenous injection at a dose of 15mg/kg significantly induced the death of 15-week-old male rats within 10 days, and caused weight loss and kidney damage in the rats[7]. A single intravenous injection of 20mg/kg dose of Nedaplatin significantly induced tumor growth in a xenograft mouse model of Ma44 cells within 12 days [8].
References:
[1] Shimada M, Itamochi H, Kigawa J. Nedaplatin: a cisplatin derivative in cancer chemotherapy[J]. Cancer management and research, 2013: 67-76.
[2] Szupryczyński K, Szefler B. Interactions of Nedaplatin with Nucleobases and Purine Alkaloids: Their Role in Cancer Therapy[J]. Biomedicines, 2025, 13(7): 1551.
[3] Su X Y, Yin H T, Li S Y, et al. Intervention effects of nedaplatin and cisplatin on proliferation and apoptosis of human tumour cells in vitro[J]. Asian Pacific Journal of Cancer Prevention, 2012, 13(9): 4531-4536.
[4] Liu Z, Liu J, Li L, et al. Inhibition of autophagy potentiated the antitumor effect of nedaplatin in cisplatin-resistant nasopharyngeal carcinoma cells[J]. PloS one, 2015, 10(8): e0135236.
[5] Li W, Hanfeng L, Zhengwen C, et al. Nedaplatin Induced Apoptosis in Human Ovarian Cancer Cisplatin-resistant Cell Lines in vitro and Investigated Its Mechanism[J]. Cancer Research on Prevention and Treatment, 2012, 39(10): 1216-1220.
[6] Zhang C, Li Y L, Weng X, et al. Nedaplatin enhanced apoptotic effects of ABT-737 in human cancer cells via Mcl-1 inhibition[J]. Oncology Letters, 2016, 12(5): 4195-4202.
[7] Uehara T, Watanabe H, Itoh F, et al. Nephrotoxicity of a novel antineoplastic platinum complex, nedaplatin: a comparative study with cisplatin in rats[J]. Archives of toxicology, 2005, 79(8): 451-460.
[8] Matsumoto M, Takeda Y, Maki H, et al. Preclinical in vivo antitumor efficacy of nedaplatin with gemcitabine against human lung cancer[J]. Japanese Journal of Cancer Research: Gann, 2001, 92(1): 51.
Protocol
| Cell experiment [1]: | |
Cell lines | HNE1 cells |
Preparation Method | HNE1 cells were cultured in RPMI-1640 medium supplemented with 10% heat-inactivated fetal bovine serum, 2mM L-glutamine, 100U/ml penicillin, 100μg/ml streptomycin in a humidified incubator at 37°C and 5% CO2. HNE1 cells were plated at a density of 6×103 cells/ml in a 96-well plate with growth medium for 24h, and then were incubated with the different concentrations of Nedaplatin (0, 1.5, 3, 6, 12, and 24 μg/ml) for 48 h, and the cell viability was analyzed. |
Reaction Conditions | 0, 1.5, 3, 6, 12, and 24μg/ml; 48h |
Applications | Nedaplatin treatment significantly inhibited cell viability of HNE1 cells in a concentration-dependent manner. |
| Animal experiment [2]: | |
Animal models | Athymic BALB/c nude mice |
Preparation Method | Female athymic BALB/c nude mice (7-week-old) were housed in an air-conditioned room with a 12h light/dark cycle and received standard laboratory rat chow and tap water. On day 0, Ma44 cells (5×105) were implanted s.c. into the back of BALB/c nude mice. Treatment was started when the tumor volume reached 100mm3. A single intravenous injection of 20mg/kg dose of Nedaplatin. Tumor size was scored throughout the experiment. |
Dosage form | 20mg/kg for once; i.v. |
Applications | Nedaplatin treatment reduced tumor volume in mice carrying Ma44 xenograft tumors. |
References: | |
Product Documents
Chemical Properties
Use stock solutions within 6 months when stored at -80°C or within 1 month when stored at -20°C.
To improve solubility, warm the tube to 37°C and sonicate it for an appropriate period.
CalculatorsMolarity / Dilution / Molecular Weight / Unit Conversion / In Vivo Formulation / Solubility
Reviews
Review for Nedaplatin
- 5 Star100%
- 4 Star0%
- 3 Star0%
- 2 Star0%
- 1 Star0%
